Jacobs Levy Equity Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Jacobs Levy Equity Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.38M	Buy	+53,636	New	+$3.43M	0.01%	496
2023 Q3	–	Sell	-41,667	Closed	-$753K	–	1060
2023 Q2	$753K	Buy	+41,667	New	+$662K	﹤0.01%	748
2022 Q4	–	Sell	-86,948	Closed	-$1.49M	–	1035
2022 Q3	$1.49M	Buy	86,948 +4,906	+6%	+$77.9K	0.01%	619
2022 Q2	$1.2M	Buy	+82,042	New	+$1.23M	0.01%	715

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management's TARS Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 53,636 shares worth $3.38M. The stake represents 0.01% of the portfolio and ranks #496 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in TARS as recently as Q2 2023.

Jacobs Levy Equity Management first reported a position in TARS in Q2 2022 and has held it in 4 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Jacobs Levy Equity Management held 53,636 shares of Tarsus Pharmaceuticals worth $3.38M as of Q2 2026.
Tarsus Pharmaceuticals was a new Jacobs Levy Equity Management position in Q2 2026.
Tarsus Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #496 holding.
Jacobs Levy Equity Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.